

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV418602979US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: November 9, 2005

Signature:

(Synthia L. Kanik, Ph.D.)

Docket No.: CCI-014CP2
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Patent Application of:
Daniella I. Zheleva *et al.*

Application No.: 10/771242

Confirmation No.: 9212

Filed: February 2, 2004

Art Unit: 1654

For: p21 PEPTIDES

Examiner: Billy D. Chism

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT (IDS)

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, but before the mailing date of a First Office Action based on the merits (37 CFR 1.97(b)(3)). Accordingly, Applicant(s) believe that no fee is due with the present submission.

For the Examiner's convenience in reviewing this continuation application, Applicants submit a consolidated PTO Form SB/08, listing all references cited during the prosecution of the parent application. The present application is a Continuation-in-Part of U.S. Serial No. 09/726470, filed November 30, 1999 (Atty. Docket No. CCI-014). References B1-B4 and C1-C17 listed on the enclosed PTO Form SB/08 have been previously cited by or submitted to the Office in the prior application, and, in accordance with 37 CFR §1.98(d), copies of these references are not enclosed but will be provided upon request. Copies of References A1 and A2

are not enclosed herewith as the requirement to submit copies of U.S. patent documents has been waived by the U.S. Patent Office.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. CCI-014CP2.

Dated: **November 9, 2005**

GAD/CLK/MG/mch

Respectfully submitted,

By 

Cynthia L. Kanik, Ph.D.

Registration No.: 37,320

LAHIVE & COCKFIELD, LLP

28 State Street

Boston, Massachusetts 02109

(617) 227-7400

(617) 742-4214 (Fax)

Attorney/Agent For Applicant



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/771242-Conf. #9212	
			Filing Date	February 2, 2004	
			First Named Inventor	Daniella I. ZHELEVA	
			Art Unit	1654	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	2	Attorney Docket Number	CCI-014CP2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1*	US-20030036628-A1	02-20-2003	Zheleva et al.	
	A2*	US-20040176301-A1	09-09-2004	Zheleva et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B1*	WO-97/42222-A1	11-13-1997	Cyclacel Limited		
	B2*	WO-96/14334-A1	05-17-1996	University of Dundee		
	B3*	WO-96/35715-A2	11-14-1996	University of Dundee		
	B4*	GB-9928323.6	11/1999	Cyclacel Limited		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1*	Adams, Peter D., et al., "Identification of Cyclin-cdk2 Recognition Motif Present in Substrates and p21-Like Cyclin-Dependent Kinase Inhibitors," <i>Molecular and Cellular Biology</i> , Vol. 16(12):6623-6633 (1996)	
	C2*	Adams, Peter D., et al., "Retinoblastoma Protein Contains a C-terminal Motif That Targets It for a Phosphorylation by Cyclin-cdk Complexes," <i>Molecular and Cellular Biology</i> , Vol. 19(2):1068-1080 (1999)	
	C3*	Ball, Kathryn L., et al., "Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1," <i>Current Biology</i> , Vol. 7:71-80 (1996)	
	C4*	Bonfanti, Marina, et al., "p21WAF1-derived Peptides Linked to an Internalization Peptide Inhibit Human Cancer Cell Growth," <i>Cancer Research</i> , Vol. 57:1442-1446 (1997)	
	C5*	Brown, Nick R., et al., "The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases," <i>Nature Cell Biology</i> , Vol. 1:438-443 (1999)	
	C6*	Chen, Junjie, et al., "Cyclin-Binding Motifs Are Essential for the Function of p21 ^{CIP1} ," <i>Molecular and Cellular Biology</i> , Vol. 16(9):4673-4682 (1996)	
	C7*	Chen, Ying-Nan P., et al., "Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 96:4325-4329 (1999)	
	C8*	Lin, Jiayuh, et al., "Analysis of Wild-Type and Mutant p21 ^{WAF-1} Gene Activities," <i>Molecular and Cellular Biology</i> , Vol. 16(4):1786-1793 (1996)	
	C9*	Mutoh, Masato, et al., "A p21 ^{Waf1/Cip1} Carboxyl-terminal Peptide Exhibited Cyclin-dependent Kinase-inhibitory Activity and Cytotoxicity When Introduced into Human Cells," <i>Cancer Research</i> , Vol. 59:3480-3488 (1999)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/771242-Conf. #9212
				Filing Date	February 2, 2004
				First Named Inventor	Daniella I. ZHELEVA
				Art Unit	1654
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	CCI-014CP2
Sheet	2	of	2		

C10*	Pin, Sokhom S., et al., "Analysis of Protein-Peptide Interaction by a Miniaturized Fluorescence Polarization Assay Using Cyclin-Dependent Kinase 2/Cyclin E as a Model System," <i>Analytical Biochemistry</i> , Vol. 275:156-161 (1999)	
C11*	Russo, Alicia A., et al., "Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex," <i>Nature</i> , Vol. 382:325-331 (1996)	
C12*	Warbick, E., et al., "PCNA binding proteins in <i>Drosophila melanogaster</i> : the analysis of a conserved PCNA binding domain," <i>Nucleic Acids Research</i> , 26(17):3925-3932 (1998)	
C13*	Database PIR 73, ACS 39358, 25 February 1994	
C14*	Database SwissProt 40, AC P38936, 15 December 1995	
C15*	Database SPTREMBL 21, AC Q14010, 01 November 1996	
C16*	Database PIR 73, AC I54380, 02 July 1996	
C17*	Database SwissProt 40, AC O19002, 15 December 1998	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--